Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder.
BACKGROUND
In Major Depressive Disorder (MDD), treatment outcomes with currently available strategies are often disappointing. Therefore, it is sensible to develop new strategies to increase remission rates in acutely depressed patients. Many studies reported that true drug response can be observed within 14 days (early improvement) of antidepressant treatment. The identical time course of symptom amelioration after early improvement in patients treated with antidepressants of all classes or with placebo strongly suggests a common biological mechanism, which is not specific for a particular antidepressant medication. However, the biology underlying early improvement and final treatment response is not understood and there is no established biological marker as yet, which can predict treatment response for the individual patient before initiation or during the course of antidepressant treatment. Peripheral blood markers and executive functions are particularly promising candidates as markers for the onset of action and thus the prediction of final treatment outcome in MDD.


METHODS
The present paper presents the rationales, objectives and methods of a multi-centre study applying close-meshed repetitive measurements of peripheral blood and neuropsychological parameters in patients with MDD and healthy controls during a study period of eight weeks for the identification of biomarkers for the onset of antidepressants' action in patients with MDD. Peripheral blood parameters and depression severity are assessed in weekly intervals from baseline to week 8, executive performance in bi-weekly intervals. Patients are participating in a randomized controlled multi-level clinical trial, healthy controls are matched according to mean age, sex and general intelligence.


CONCLUSIONS
This investigation will help to identify a biomarker or a set of biomarkers with decision-making quality in the treatment of MDD in order to increase the currently disappointing remission rates of antidepressant treatment.
Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.
André
A
Tadić
Stefanie
S
Wagner
Stanislav
S
Gorbulev
Norbert
N
Dahmen
Christoph
C
Hiemke
Dieter F
DF
Braus
Klaus
K
Lieb
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D003865:Major Depressive Disorder / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D056344:Executive Function; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests / Q000706:statistics & numerical data*; D011379:Prognosis; D011788:Quality of Life / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000928:Antidepressive Agents; D015415:Biomarkers
J Clin Psychiatry. 2003 Dec;64(12):1465-75
14728109
J Clin Psychiatry. 2007 Aug;68(8):1195-205
17854243
Br Med Bull. 2003;65:193-207
12697626
PLoS One. 2010 Feb 11;5(2):e9166
20161799
Trials. 2010 Feb 26;11:21
20187947
PLoS Med. 2006 Nov;3(11):e442
17132052
Fortschr Neurol Psychiatr. 2000 Jan;68(1):1-11
10705569
J Affect Disord. 2005 Dec;89(1-3):125-35
16324752
J Affect Disord. 2003 Oct;77(1):65-9
14550936
Am J Psychiatry. 1997 Jan;154(1):4-17
8988952
Psychopathology. 2011;44(1):68-70
21072002
JAMA. 2010 Jan 6;303(1):47-53
20051569
J Clin Psychiatry. 2005 Feb;66(2):148-58
15704999
Biol Psychiatry. 2000 Oct 15;48(8):830-43
11063978
J Nerv Ment Dis. 1997 Dec;185(12):748-54
9442186
J Clin Psychopharmacol. 2006 Feb;26(1):56-60
16415707
Dialogues Clin Neurosci. 2009;11(4):435-46
20135901
N Engl J Med. 2008 Jan 17;358(3):252-60
18199864
J Psychiatr Res. 2005 Mar;39(2):129-35
15589560
J Affect Disord. 2004 Oct 15;82(2):253-8
15488254
Arch Clin Neuropsychol. 2002 Aug;17(6):547-65
14591855
Psychol Med. 1996 May;26(3):477-86
8733206
Nat Rev Neurosci. 2008 Aug;9(8):638-46
18628772
J Clin Psychiatry. 2003 Apr;64(4):413-20
12716243
Acta Psychiatr Scand Suppl. 2004;(420):21-7
15128384
J Nerv Ment Dis. 1980 May;168(5):297-304
7365494
J Affect Disord. 2010 Jan;120(1-3):86-93
19428118
Arch Gen Psychiatry. 2006 Nov;63(11):1217-23
17088502
J Clin Psychiatry. 2009 Mar;70(3):344-53
19254516
J Int Neuropsychol Soc. 1997 Nov;3(6):631-51
9448376
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
J Affect Disord. 2009 Jun;115(3):439-49
19027961
World J Biol Psychiatry. 2007;8(2):67-104
17455102
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
10767867
Biol Psychiatry. 1996 Dec 15;40(12):1282-7
8959293
Am J Psychiatry. 2000 Sep;157(9):1423-8
10964858
J Psychiatr Res. 2009 Jan;43(3):215-29
18586274
Arch Gen Psychiatry. 1987 Mar;44(3):259-64
3548638
Arch Gen Psychiatry. 1984 Aug;41(8):782-6
6378117
Neuropsychopharmacology. 2004 Dec;29(12):2266-71
15340392
Neuropsychopharmacology. 2004 Mar;29(3):566-79
14627997
World J Biol Psychiatry. 2007;8(3):141-74
17654407
J Neural Transm (Vienna). 2008 Aug;115(8):1213-9
18629432
J Affect Disord. 2008 Nov;111(1):46-51
18304646
Curr Psychiatry Rep. 2007 Dec;9(6):449-59
18221624
J Clin Exp Neuropsychol. 1997 Aug;19(4):587-603
9342691
J Ment Health Policy Econ. 2006 Jun;9(2):87-98
17007486
PLoS Med. 2008 Feb;5(2):e45
18303940
JAMA. 2003 Jun 18;289(23):3095-105
12813115
Encephale. 2002 Mar-Apr;28(2):97-107
11972136